Business Context and Reporting Period
Company: Starry Sea Acquisition Corp (SSEA), a Cayman Islands exempted company and emerging growth company.
Filing Type: Form 8-K (Current Report).
Date of Report: August 22, 2026.
Event: Entry into a Material Definitive Agreement (Agreement and Plan of Merger) to acquire SuperiorMed Holdings Limited ("SuperiorMed"), a healthcare company. The transaction involves a dual merger structure where SSEA merges into a wholly-owned subsidiary (Purchaser), and a Merger Sub merges into SuperiorMed.
Key Financial Metrics and Transaction Terms
Acquisition Consideration: The aggregate consideration for SuperiorMed is based on an agreed net value of $200,000,000. This will be paid in newly issued Purchaser Ordinary Shares calculated at $10.00 per share.
Capital Structure Post-Closing:
- Share Conversion: Each SSEA ordinary share converts to one Purchaser Class A Ordinary Share (1 vote).
- Right Conversion: Each SSEA Right converts to one Purchaser Right, which is subsequently cancelled in exchange for 1/6 of one Purchaser Class A Ordinary Share.
- Class B Shares: Purchaser Class B Ordinary Shares will be issued with 10 votes per share.
Board Composition: The post-closing board will consist of 5 directors: 1 designated by SSEA (independent) and 4 designated by SuperiorMed (including Dale Li and 2 independent directors).
Financial Statements: This filing does not provide specific revenue, profit, cash flow, or debt metrics for either SSEA or SuperiorMed. It references that SuperiorMed will deliver financial statements as a covenant but does not disclose the values herein.
Material Changes and Transaction Mechanics
Corporate Restructuring: SSEA will cease to exist as a separate entity, merging into the Purchaser. SuperiorMed will survive the merger as a wholly-owned subsidiary of the Purchaser.
Shareholder Support: Principal shareholders of SuperiorMed have entered into a Shareholder Support Agreement, agreeing to vote in favor of the transaction and not transfer shares prior to closing.
Lock-Up Provisions: SuperiorMed's founder and management shareholders, along with the Sponsor, are subject to a lock-up agreement. Restrictions last until the earlier of:
- 180 days after Closing; or
- The date the closing price of Purchaser Class A Ordinary Shares equals or exceeds $12.00 per share for 20 trading days within a 30-day period.
Guidance, Outlook, Risks, and Conditions
Conditions to Closing: The transaction is subject to numerous conditions, including:
- Shareholder approval from both SSEA and SuperiorMed.
- SEC declaration of effectiveness for the Registration Statement (Form F-4 or S-4).
- Completion of a restructuring ensuring SuperiorMed owns 100% of the Dubai Subsidiary.
- Receipt of required governmental approvals and legal opinions.
- Absence of a Material Adverse Effect on either party.
Termination Rights: The agreement may be terminated if regulatory approvals are not obtained, if shareholder approval fails, or if the Closing does not occur by the "Outside Date" (the later of May 7, 2027, or the end of SSEA's combination period).
Risks and Forward-Looking Statements: The filing includes standard forward-looking statements regarding the anticipated benefits of the combination. Key risks identified include the failure to obtain regulatory or shareholder approvals, inability to list on Nasdaq/NYSE post-merger, disruption of operations, and general economic factors.
Investor Verification Checklist
- Proxy Statement: Verify the final terms and risk factors in the upcoming Form F-4 or S-4 proxy statement/prospectus.
- SuperiorMed Financials: Review the audited financial statements of SuperiorMed to be delivered under the covenants, as no historical financial data is provided in this 8-K.
- Regulatory Approvals: Monitor the status of required governmental approvals, particularly given SuperiorMed's operations in the UAE (Dubai Subsidiary) and Cayman Islands.
- Shareholder Vote: Confirm the record date and voting procedures for the special meeting of SSEA shareholders.
- PIPE Investment: Verify the status and terms of any Private Investment in Public Equity (PIPE) mentioned in the covenants, as specific amounts are not detailed in this summary.